CIK 0001576263
MRTX Mirati Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jan 25, 2024.
In brief
Mirati Therapeutics, Inc. (MRTX) has 34 SEC Form 4 filings on file from 15 insiders, the latest filed on Jan 25, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 open-market trades have been scored at MRTX. The newest: Jamie Christensen (EVP & Chief Scientific Officer) sold $94k of stock on Jan 16, 2024, filed Jan 18, 2024, scored 33 (weak). The largest of the 6 shown: Jamie Christensen (EVP & Chief Scientific Officer) sold $137k on Dec 18, 2023, scored 34 (weak). 2 insiders sold within 14 days of each other around Jan 16, 2024.
Last 90 days
Signals
Open-market buys and sells at Mirati Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Jamie Christensen EVP & Chief Scientific Officer sell | $94k 1,597 shares | -1% | - | |
| 33Weak | Benjamin Hickey EVP, Chief Commercial Officer sell | $94k 1,597 shares | -1% | - | |
| 33Weak | Benjamin Hickey EVP, Chief Commercial Officer sell | $123k 2,090 shares | -2% | - | |
| 32Weak | Jamie Christensen EVP & Chief Scientific Officer sell | $90k 1,531 shares | -1% | - | |
| 34Weak | Jamie Christensen EVP & Chief Scientific Officer sell | $137k 2,387 shares | -2% | - | |
| 34Weak | Benjamin Hickey EVP, Chief Commercial Officer sell | $126k 2,220 shares | -2% | - |
Transactions
The newest 50 of 117 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Boxer Capital, LLC other | DDisposition to issuer Common Stockindirect: See Footnote | -287,866 | - | - | 0 | Jan 25, 2024 |
| Jan 23, 2024 | Boxer Capital, LLC other | DDisposition to issuer Common Stock | -3,201,440 | - | - | 0 | Jan 25, 2024 |
| Jan 23, 2024 | Boxer Capital, LLC other | DDisposition to issuer Common Stockindirect: See Footnote | -203,754 | - | - | 0 | Jan 25, 2024 |
| Jan 23, 2024 | Boxer Capital, LLC other | DDisposition to issuer Common Stockindirect: See Footnote | -3,135,966 | - | - | 0 | Jan 25, 2024 |
| Jan 23, 2024 | Boxer Capital, LLC other | DDisposition to issuer Common Stockindirect: See Footnote | -30,518 | - | - | 0 | Jan 25, 2024 |
| Jan 23, 2024 | Boxer Capital, LLC other | DDisposition to issuer Warrant (right to purchase)derivative | -332,809 | - | - | 0 | Jan 25, 2024 |
| Jan 23, 2024 | Boxer Capital, LLC other | DDisposition to issuer Warrant (right to purchase)derivativeindirect: See Footnote | -3,578,036 | - | - | 0 | Jan 25, 2024 |
| Jan 23, 2024 | Boxer Capital, LLC other | DDisposition to issuer Warrant (right to purchase)derivativeindirect: See Footnote | -1,413,475 | - | - | 0 | Jan 25, 2024 |
| Jan 23, 2024 | Benjamin Hickey EVP, Chief Commercial Officer | DDisposition to issuer Common Stock | -27,801 | - | - | 89,227 | Jan 23, 2024 |
| Jan 23, 2024 | Charles M Baum Founder, President, and CEO | DDisposition to issuer Common Stock | -123,389 | - | - | 114,482 | Jan 23, 2024 |
| Jan 23, 2024 | Faheem Hasnain director | DDisposition to issuer Common Stock | -8,717 | - | - | 16,035 | Jan 23, 2024 |
| Jan 23, 2024 | John B Moriarty Chief Legal Officer | DDisposition to issuer Common Stock | -675 | - | - | 71,660 | Jan 23, 2024 |
| Jan 23, 2024 | Bruce L A Carter director | DDisposition to issuer Common Stock | -6,021 | - | - | 11,252 | Jan 23, 2024 |
| Jan 23, 2024 | Carol Giltner Gallagher director | DDisposition to issuer Common Stock | -7,555 | - | - | 6,808 | Jan 23, 2024 |
| Jan 23, 2024 | Alan B. Sandler Chief Medical Officer | DDisposition to issuer Common Stock | -10,547 | - | - | 69,318 | Jan 23, 2024 |
| Jan 23, 2024 | Craig A Johnson director | DDisposition to issuer Common Stock | -6,021 | - | - | 11,252 | Jan 23, 2024 |
| Jan 23, 2024 | Maria E Martinez director | DDisposition to issuer Common Stock | -6,021 | - | - | 11,252 | Jan 23, 2024 |
| Jan 23, 2024 | Aaron I. Davis director | DDisposition to issuer Common Stock | -43,073 | - | - | 11,252 | Jan 23, 2024 |
| Jan 23, 2024 | Julie M Cherrington director | DDisposition to issuer Common Stock | -4,444 | - | - | 6,808 | Jan 23, 2024 |
| Jan 23, 2024 | Shalini Sharp director | DDisposition to issuer Common Stock | -4,162 | - | - | 12,060 | Jan 23, 2024 |
| Jan 23, 2024 | Jamie Christensen EVP & Chief Scientific Officer | DDisposition to issuer Common Stock | -56,495 | - | - | 98,501 | Jan 23, 2024 |
| Jan 23, 2024 | Aaron Ondrey Chief Financial Officer | DDisposition to issuer Common Stock | -1,302 | - | - | 38,159 | Jan 23, 2024 |
| Jan 23, 2024 | Shalini Sharp director | DDisposition to issuer Common Stock | -5,252 | - | - | 6,808 | Jan 23, 2024 |
| Jan 23, 2024 | Benjamin Hickey EVP, Chief Commercial Officer | DDisposition to issuer Common Stock | -72,206 | - | - | 17,021 | Jan 23, 2024 |
| Jan 23, 2024 | Craig A Johnson director | DDisposition to issuer Common Stock | -4,444 | - | - | 6,808 | Jan 23, 2024 |
| Jan 23, 2024 | Charles M Baum Founder, President, and CEO | DDisposition to issuer Common Stock | -94,057 | - | - | 20,425 | Jan 23, 2024 |
| Jan 23, 2024 | Bruce L A Carter director | DDisposition to issuer Common Stock | -4,444 | - | - | 6,808 | Jan 23, 2024 |
| Jan 23, 2024 | Carol Giltner Gallagher director | DDisposition to issuer Common Stock | -6,808 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Faheem Hasnain director | DDisposition to issuer Common Stock | -6,333 | - | - | 9,702 | Jan 23, 2024 |
| Jan 23, 2024 | Aaron I. Davis director | DDisposition to issuer Common Stock | -4,444 | - | - | 6,808 | Jan 23, 2024 |
| Jan 23, 2024 | Alan B. Sandler Chief Medical Officer | DDisposition to issuer Common Stock | -52,297 | - | - | 17,021 | Jan 23, 2024 |
| Jan 23, 2024 | Julie M Cherrington director | DDisposition to issuer Common Stock | -6,808 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | John B Moriarty Chief Legal Officer | DDisposition to issuer Common Stock | -71,660 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Maria E Martinez director | DDisposition to issuer Common Stock | -4,444 | - | - | 6,808 | Jan 23, 2024 |
| Jan 23, 2024 | Aaron Ondrey Chief Financial Officer | DDisposition to issuer Common Stock | -21,138 | - | - | 17,021 | Jan 23, 2024 |
| Jan 23, 2024 | Jamie Christensen EVP & Chief Scientific Officer | DDisposition to issuer Common Stock | -81,480 | - | - | 17,021 | Jan 23, 2024 |
| Jan 23, 2024 | Maria E Martinez director | DDisposition to issuer Common Stock | -6,808 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Benjamin Hickey EVP, Chief Commercial Officer | DDisposition to issuer Common Stock | -17,021 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Shalini Sharp director | DDisposition to issuer Common Stock | -6,808 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Faheem Hasnain director | DDisposition to issuer Common Stock | -9,702 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Craig A Johnson director | DDisposition to issuer Common Stock | -6,808 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Carol Giltner Gallagher director | DDisposition to issuer Option to Purchase Common Stockderivative | -12,784 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Bruce L A Carter director | DDisposition to issuer Common Stock | -6,808 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Aaron Ondrey Chief Financial Officer | DDisposition to issuer Common Stock | -17,021 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Aaron I. Davis director | DDisposition to issuer Common Stock | -6,808 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Alan B. Sandler Chief Medical Officer | DDisposition to issuer Common Stock | -17,021 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | John B Moriarty Chief Legal Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -83,525 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Julie M Cherrington director | DDisposition to issuer Option to Purchase Common Stockderivative | -7,520 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Charles M Baum Founder, President, and CEO | DDisposition to issuer Common Stock | -20,425 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | Jamie Christensen EVP & Chief Scientific Officer | DDisposition to issuer Common Stock | -17,021 | - | - | 0 | Jan 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Charles M BaumFounder, President, and CEO
- Boxer Capital, LLCother, director
- Bruce L A Carterdirector
- Julie M Cherringtondirector
- Jamie ChristensenEVP & Chief Scientific Officer
- Aaron I. Davisother, director
- Carol Giltner Gallagherdirector
- Faheem Hasnainceo, president, officer, director
- Benjamin HickeyEVP, Chief Commercial Officer
- Craig A Johnsondirector
- Maria E Martinezdirector
- John B MoriartyChief Legal Officer
- Aaron OndreyChief Financial Officer
- Alan B. SandlerChief Medical Officer
- Shalini Sharpdirector
Questions about MRTX
Answered from the filings on this page, as of the latest one.
Are insiders buying MRTX?
No. In the last 90 days no insider at Mirati Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MRTX on the open market?
Jamie Christensen (EVP & Chief Scientific Officer) sold $94k of MRTX on Jan 16, 2024 and filed the Form 4 on Jan 18, 2024. InsiderTell scored 33 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Mirati Therapeutics, Inc.?
15 people have filed a Form 4 at Mirati Therapeutics, Inc., among them Charles M Baum (Founder, President, and CEO), Boxer Capital, LLC (director), Bruce L A Carter (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.